Business Wire

Craig Lipset is Appointed Chairman of the Trialbee Industry Advisory Board

Share

Trialbee, the leading global data and technology platform provider for patient matching and enrollment in clinical trials, today announced the appointment of Craig Lipset as Chairman of the Trialbee Industry Advisory Board. Craig is a recognized visionary leader who has spent his career dedicated to transforming some of the most challenging issues in clinical research through new innovations.

Craig is the former Head of Clinical Innovation and Venture Partner at Pfizer and a distinguished leader at the forefront of innovation in clinical research and medicine development. Most recently Craig cofounded and co-Chairs the Decentralized Trials & Research Alliance (DTRA), which roughly 100 leading life science organizations have joined the first few months since it was established. The core mission of DTRA is making clinical trial participation widely accessible by advancing policies, research practices and new technologies in decentralized clinical research.

A significant barrier to patient participation in clinical research is awareness and access. Trialbee’s patient focused platform is changing that paradigm. Powered by Hive™, the company’s data-driven engine for matching patients globally, Trialbee is leading the world towards broader patient awareness and participation in clinical trials.

“I am proud to be part of a team that embraces digital and operational innovations in a pragmatic way, maintaining focus on patients while providing benefits for industry innovators and the healthcare community. I am honored to lead a global and diverse expert panel that will provide insights and guidance on advancing new and better solutions to engage patients in the development of new treatments. Digital solutions are democratizing trial participation to enable equity and diversity, and these approaches demand equally innovative approaches to engaging patients and realize the vision of improving research access for all,” said Craig Lipset.

Craig brings over 20 years of leadership and innovation in the field of drug development. He served on the founding Operations Committee at TransCelerate Biopharma and has been listed among the PharmaVOICE most inspiring people in life sciences, Pharmaceutical Executive’s Emerging Leaders, CenterWatch Top Innovators, and AlleyWatch Who's Who in eHealth.

“We are honored to have Craig as the chair of our Industry Advisory Board. This is a strategic role that will guide Trialbee as we reimagine the patients journey into clinical research through new, innovative and data-driven solutions, such as Hive,” said Matt Walz, CEO of Trialbee. “The adoption of decentralized trial designs has paved the way for patient access to clinical research. Trialbee is achieving greater global reach and scale of patient matching and enrollment to improve awareness and participation. The investments we are making in data science are driving material improvements to representative population sampling and driving diversity in clinical trials. I cannot think of a more knowledgeable and capable innovator than Craig to help guide us as we continue to build out our patient matching and enrolling platforms.”

In addition to Trialbee, Craig’s other prominent engagements include serving on the Board of Directors for the Decentralized Trials & Research Alliance (Co-Chair), MedStar Health Research Institute, as well as on the Editorial Board for Therapeutic Innovation & Regulatory Science. He is an Adjunct Assistant Professor in Health Informatics at Rutgers University and an Adjunct Instructor at the University of Rochester Center for Health & Technology.

About Trialbee

Trialbee is the leading global data and technology platform for patient matching and enrollment in clinical trials. Hive™ operationalizes real world data (RWD) and applies data science to match patients globally. Our Candidate Manager platform simplifies the journey for matched patients to participate in clinical research. Partnering with Sponsors, CROs and virtual/decentralized sites and software providers, Trialbee is achieving patient enrollment goals and driving enhancements in diversity in clinical trial populations. We are the smartest way to match and enroll patients for your clinical trial. For more information, visit www.trialbee.com or contact us at solutions@trialbee.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Kristi Lee-John for Trialbee
Tel.: +1 919-270-8054
klee@crossroadsb2b.com

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Mundipharma acquires all assets and rights related to REZZAYO ® (rezafungin) , reinforcing continued commitment to management of infectious diseases and specialty care therapeutic area24.4.2024 22:01:00 CEST | Press release

Mundipharma* today announced the acquisition of all assets and rights related to rezafungin globally from Cidara Therapeutics. This provides Mundipharma with global ownership of rezafungin including ongoing development and distribution. Rezafunginis a novel once-weekly echinocandin indicated for the treatment of invasive candidiasis in adults.1 Invasive candidiasis, is a severe, life-threatening infection of the bloodstream and/or deep/visceral tissues.2,3 It affects seriously ill people, especially those with a weakened immune systemand the mortality rate can be 40%4 or more.5,6 It can place a large burden on the healthcare system, with the potential for extended treatment regimens and long hospital stays.6 Over the last 15 years, there have been no new treatments and morbidity and mortality rates remain largely the same, indicating the need for alternative treatment options.7,8 “This acquisition places Mundipharma in the best position to realise the full potential of rezafungin inclu

Global Oncology Innovator BeiGene Highlights New Data across Hematology and Solid Tumor Portfolio at 2024 ASCO Annual Meeting24.4.2024 22:01:00 CEST | Press release

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will share research outcomes from its broad hematology and solid tumor portfolio at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, May 31 - June 4, 2024. “Our presentations at this year’s ASCO highlight the strength of our growing oncology portfolio and our commitment to developing treatments that address the unmet needs of patients with B-cell malignancies and solid tumors,” Mehrdad Mobasher, M.D., M.P.H., Chief Medical Officer, Hematology at BeiGene. “The exciting data we will share during ASCO showcase BRUKINSA’s uniquely differentiated clinical profile and add to the growing body of evidence supporting its role across the blood cancer treatment paradigm.” BeiGene will share new data for BRUKINSA (zanubrutinib), which add to the robust efficacy and safety evidence differentiating it within the BTK class. Key highlights include: A network meta-analysis co

TSMC Celebrates 30 th North America Technology Symposium with Innovations Powering AI with Silicon Leadership24.4.2024 21:30:00 CEST | Press release

TSMC (TWSE: 2330, NYSE: TSM) today unveiled its newest semiconductor process, advanced packaging, and 3D IC technologies for powering the next generation of AI innovations with silicon leadership at the Company’s 2024 North America Technology Symposium. TSMC debuted the TSMC A16TM technology, featuring leading nanosheet transistors with innovative backside power rail solution for production in 2026, bringing greatly improved logic density and performance. TSMC also introduced its System-on-Wafer (TSMC-SoW™) technology, an innovative solution to bring revolutionary performance to the wafer level in addressing the future AI requirements for hyperscaler datacenters. This year marks the 30th anniversary of TSMC’s North America Technology Symposium, and more than 2,000 attended the event, growing from less than 100 attendees 30 years ago. The North America Technology Symposium in Santa Clara, California kicks off TSMC Technology Symposiums around the world in the coming months. The symposiu

Rimini Street Appoints Steve Hershkowitz as Chief Revenue Officer24.4.2024 18:50:00 CEST | Press release

Rimini Street, Inc. (Nasdaq: RMNI), a global provider of end-to-end enterprise software support, products, and services, the leading third-party support provider for Oracle and SAP software, and a Salesforce and AWS partner, today announced the appointment of Steve Hershkowitz as its new Chief Revenue Officer (CRO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240424061249/en/ Rimini Street Appoints Steve Hershkowitz as Chief Revenue Officer (Photo: Business Wire) “Steve’s leadership and extensive experience scaling businesses to deliver top-line growth will expand our sales reach to capture new logos and increase our opportunity to provide even greater value to our clients,” said Rimini Street president and CEO Seth Ravin. “The global revenue team and I are excited to work closely together with Steve to drive growth and broader capabilities for our company.” Leading the Next Chapter of Sales Growth and Continued Success f

Hithium Hosts Roundtable at the BNEF Summit New York, Discussing Next Generation Battery Energy Storage System24.4.2024 18:00:00 CEST | Press release

From April 16th to 17th, the BloombergNEF (BNEF) Summit was held in New York, USA. The BNEF Summit brings together energy, finance, and technology professionals to facilitate the exchange of ideas, insights, and connections. This was Hithium's first time attending after its global launch in 2023. Hithium was also invited to host a roundtable discussion on the topic of "Next Generation Battery Energy Storage System: Latest Technology Trends and Impact on Project Economics," led by Hithium Director of Global Applications Engineering, Neil Bradshaw. The discussion focused on the future development trends of energy storage and included insights on Hithium's technology innovations, global application practices, and international development for global energy green transformation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240423336349/en/ BNEF summit roundtable hosted by HiTHIUM (Photo: Business Wire) Hithium’s advantages on

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye